OpGen, Inc. (NASDAQ:OPGN) Short Interest Down 17.5% in June

OpGen, Inc. (NASDAQ:OPGN) was the target of a large decline in short interest during the month of June. As of June 15th, there was short interest totalling 30,700 shares, a decline of 17.5% from the May 31st total of 37,200 shares. Based on an average daily volume of 175,600 shares, the days-to-cover ratio is presently 0.2 days. Approximately 2.4% of the shares of the company are sold short.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in OpGen stock. Chase Investment Counsel Corp acquired a new stake in shares of OpGen, Inc. (NASDAQ:OPGN) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned about 2.63% of OpGen as of its most recent filing with the SEC. 2.68% of the stock is owned by hedge funds and other institutional investors.

OpGen Trading Up 2.4 %

NASDAQ OPGN traded up $0.06 on Tuesday, hitting $2.56. 3,257 shares of the company’s stock traded hands, compared to its average volume of 99,583. The firm has a market capitalization of $3.43 million, a PE ratio of -0.04 and a beta of -0.65. OpGen has a 1-year low of $1.65 and a 1-year high of $38.40. The firm’s 50-day moving average price is $3.59 and its two-hundred day moving average price is $4.36.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on OpGen in a report on Saturday, May 25th. They set a “sell” rating for the company.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.